TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH EXTERNAL BEAM RADIATION THERAPY
Author(s)
Gordon Brown, MD1, Charmi Patel, MPH2, Carmine Rossi, PhD3, Sabree Burbage, MPH, PharmD4, Frédéric Kinkead, MSc3, Francesca Lee, MSc3, Yuxi Wang, MSc3, Dominic Pilon, MA3, Benjamin Lowentritt, MD5;
1New Jersey Urology, Sewell, NJ, USA, 2Johnson & Johnson, Horsham, PA, USA, 3Analysis Group, Inc., Montreal, QC, Canada, 4Johnson and Johnson, Horsham, PA, USA, 5Chesapeake Urology, Towson, MD, USA
1New Jersey Urology, Sewell, NJ, USA, 2Johnson & Johnson, Horsham, PA, USA, 3Analysis Group, Inc., Montreal, QC, Canada, 4Johnson and Johnson, Horsham, PA, USA, 5Chesapeake Urology, Towson, MD, USA
OBJECTIVES: To characterize healthcare costs for patients with localized prostate cancer (LPC) treated with external beam radiation therapy (EBRT) in the United States (US), overall, and stratified by HR and low-/intermediate-risk (L/IR) status.
METHODS: Clinical data from electronic medical records sourced from private, US community-based urology practices (PPS Analytics) were linked with administrative claims data (Komodo Research Database; study period 1/1/2016-8/31/2024). The date of the first claim for EBRT defined the index date. LPC risk status (i.e., HR vs L/IR) was based on NCCN Guidelines incorporating tumor staging, Gleason score, and prostate-specific antigen levels. Patients with metastasis, castration resistance, prior advanced treatment, or <12 months of continuous pre-index insurance enrollment were excluded. Baseline (i.e., 12-month pre-index) and post-index total healthcare costs (i.e., medical and pharmacy) per-patient-per-year (PPPY; 2024 USD) were described from the payer’s perspective.
RESULTS: Overall, 980 HR LPC patients (mean age 71 years, 45% White, 20% Black, mean Quan-CCI 3.7) and 1,862 L/IR LPC patients (mean age 68 years, 46% White, 17% Black, mean Quan-CCI 3.5) treated with EBRT were identified. Mean total baseline costs were $14,092 PPPY (HR) and $13,082 PPPY (L/IR). Total healthcare costs were numerically higher for HR LPC patients ($45,576 PPPY) than L/IR LPC patients ($39,442 PPPY), overall, and during the LPC period prior to recurrence or progression (HR: $44,964 PPPY; L/IR: $39,769), with high costs being observed during the first 90 days of treatment (HR: $37,321; L/IR: $35,515). Among patients with metastasis, mean total costs from progression remained numerically higher for HR LPC patients (n=54; $89,920 PPPY) than L/IR LPC patients (n=23; $35,096 PPPY).
CONCLUSIONS: Patients with LPC treated with EBRT experienced substantial healthcare costs, specifically among those with HR LPC. Total healthcare costs increased from the pre-index, LPC, and post-metastasis periods for patients with HR LPC, suggesting an unmet treatment need for patients treated with EBRT.
METHODS: Clinical data from electronic medical records sourced from private, US community-based urology practices (PPS Analytics) were linked with administrative claims data (Komodo Research Database; study period 1/1/2016-8/31/2024). The date of the first claim for EBRT defined the index date. LPC risk status (i.e., HR vs L/IR) was based on NCCN Guidelines incorporating tumor staging, Gleason score, and prostate-specific antigen levels. Patients with metastasis, castration resistance, prior advanced treatment, or <12 months of continuous pre-index insurance enrollment were excluded. Baseline (i.e., 12-month pre-index) and post-index total healthcare costs (i.e., medical and pharmacy) per-patient-per-year (PPPY; 2024 USD) were described from the payer’s perspective.
RESULTS: Overall, 980 HR LPC patients (mean age 71 years, 45% White, 20% Black, mean Quan-CCI 3.7) and 1,862 L/IR LPC patients (mean age 68 years, 46% White, 17% Black, mean Quan-CCI 3.5) treated with EBRT were identified. Mean total baseline costs were $14,092 PPPY (HR) and $13,082 PPPY (L/IR). Total healthcare costs were numerically higher for HR LPC patients ($45,576 PPPY) than L/IR LPC patients ($39,442 PPPY), overall, and during the LPC period prior to recurrence or progression (HR: $44,964 PPPY; L/IR: $39,769), with high costs being observed during the first 90 days of treatment (HR: $37,321; L/IR: $35,515). Among patients with metastasis, mean total costs from progression remained numerically higher for HR LPC patients (n=54; $89,920 PPPY) than L/IR LPC patients (n=23; $35,096 PPPY).
CONCLUSIONS: Patients with LPC treated with EBRT experienced substantial healthcare costs, specifically among those with HR LPC. Total healthcare costs increased from the pre-index, LPC, and post-metastasis periods for patients with HR LPC, suggesting an unmet treatment need for patients treated with EBRT.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE462
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology